Literature DB >> 33689008

Imaging diagnosis of classical and new pneumoconiosis: predominant reticular HRCT pattern.

Akira Masanori1.   

Abstract

Our understanding of the manifestations of pneumoconioses is evolving in recent years. Associations between novel exposures and diffuse interstitial lung disease have been newly recognized. In advanced asbestosis, two types of fibrosis are seen, probably related to dose of exposure, existence of pleural fibrosis, and the host factor status of the individual. In pneumoconiosis of predominant reticular type, nodular opacities are often seen in the early phase. The nodular pattern is centrilobular, although some in metal lung show perilymphatic distribution, mimicking sarcoidosis. High-resolution computed tomography enables a more comprehensive correlation between the pathologic findings and clinically relevant imaging findings. The clinician must understand the spectrum of characteristic imaging features related to both known dust exposures and to historically recent new dust exposures.

Entities:  

Keywords:  Asbestosis; HRCT; Metal lung disease; Pneumoconiosis

Year:  2021        PMID: 33689008     DOI: 10.1186/s13244-021-00966-y

Source DB:  PubMed          Journal:  Insights Imaging        ISSN: 1869-4101


  47 in total

1.  Deposition and clearance of inhaled fibrous minerals in the rat. Studies using radioactive tracer techniques.

Authors:  A Morgan; J C Evans; A Holmes
Journal:  Inhaled Part       Date:  1975-09

2.  Early asbestosis: evaluation with high-resolution CT.

Authors:  M Akira; K Yokoyama; S Yamamoto; T Higashihara; K Morinaga; N Kita; S Morimoto; J Ikezoe; T Kozuka
Journal:  Radiology       Date:  1991-02       Impact factor: 11.105

3.  Lung Pathology in U.S. Coal Workers with Rapidly Progressive Pneumoconiosis Implicates Silica and Silicates.

Authors:  Robert A Cohen; Edward L Petsonk; Cecile Rose; Byron Young; Michael Regier; Asif Najmuddin; Jerrold L Abraham; Andrew Churg; Francis H Y Green
Journal:  Am J Respir Crit Care Med       Date:  2016-03-15       Impact factor: 21.405

4.  Asbestos-related pleural and parenchymal fibrosis: detection with high-resolution CT.

Authors:  D R Aberle; G Gamsu; C S Ray; I M Feuerstein
Journal:  Radiology       Date:  1988-03       Impact factor: 11.105

5.  Histopathological features of pulmonary asbestosis with particular emphasis on the comparison with those of usual interstitial pneumonia.

Authors:  S Yamamoto
Journal:  Osaka City Med J       Date:  1997-12

Review 6.  Newly recognized occupational and environmental causes of chronic terminal airways and parenchymal lung disease.

Authors:  Maor Sauler; Mridu Gulati
Journal:  Clin Chest Med       Date:  2012-12       Impact factor: 2.878

7.  CT quantification of interstitial fibrosis in patients with asbestosis: a comparison of two methods.

Authors:  G Gamsu; C J Salmon; M L Warnock; P D Blanc
Journal:  AJR Am J Roentgenol       Date:  1995-01       Impact factor: 3.959

8.  The burden of exposure-related diffuse lung disease.

Authors:  Sheryl R Goldyn; Rany Condos; William N Rom
Journal:  Semin Respir Crit Care Med       Date:  2009-02-16       Impact factor: 3.119

9.  Asbestosis: high-resolution CT-pathologic correlation.

Authors:  M Akira; S Yamamoto; K Yokoyama; N Kita; K Morinaga; T Higashihara; T Kozuka
Journal:  Radiology       Date:  1990-08       Impact factor: 11.105

10.  Pathology of asbestosis- An update of the diagnostic criteria: Report of the asbestosis committee of the college of american pathologists and pulmonary pathology society.

Authors:  Victor L Roggli; Allen R Gibbs; Richard Attanoos; Andrew Churg; Helmut Popper; Philip Cagle; Bryan Corrin; Teri J Franks; Francoise Galateau-Salle; Jeff Galvin; Philip S Hasleton; Douglas W Henderson; Koichi Honma
Journal:  Arch Pathol Lab Med       Date:  2010-03       Impact factor: 5.534

View more
  1 in total

Review 1.  Early Identification, Accurate Diagnosis, and Treatment of Silicosis.

Authors:  Tian Li; Xinyu Yang; Hong Xu; Heliang Liu
Journal:  Can Respir J       Date:  2022-04-25       Impact factor: 2.130

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.